On November 29, EIT Jumpstarter hosted the Grand Final of its accelerator programme, which aims to create a sustainable impact in the Central-Eastern and...

<!----> GE Healthcare has collaborated with augmented reality (AR) med-tech company MediView XR to develop the OmnifyXR Interventional...

Many IoT and medical devices are affected by seven potentially serious vulnerabilities discovered in widely used remote management software, according to enterprise security company Forescout.

read more

As many as seven security vulnerabilities have been disclosed in PTC's Axeda software that could be weaponized to gain unauthorized access to medical and IoT devices. Collectively called "Access:7," the weaknesses – three of which are rated Critical in severity – potentially affect more than 150 device models spanning over 100 different manufacturers, posing a significant supply chain risk.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners.

GE Digital has released patches and mitigations for two high-severity vulnerabilities affecting its Proficy CIMPLICITY HMI/SCADA software, which is used by plants around the world to monitor and control operations.

read more

You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Fascinated seeing great companies like Sony, Coca-Cola, Apple since childhood, Paras realized...

Chimeric antigen receptor (CAR) T cells have revolutionized cancer treatment. CARs use antibody-derived binding domains to redirect T cells to antigens expressed on the surface of cancer cells. However, the high affinity of most currently used CAR-binding domains results in excessive T-cell activation limiting CAR T-cell persistence and the inability to differentiate between antigen-high tumor cells and antigen-low healthy cells. We review recent data on the use of low-affinity CAR-binding domains and evaluate technologies and approaches to engineer and screen low-affinity antibody variants for CAR T-cell development.

DUBLIN–(BUSINESS WIRE)–The “Global Genetic Testing Market Forecasts for Applications and Technologies 2021-2025 – COVID-19 Pandemic Impact Updates with Executive and Consultant Guides” report has been added to ResearchAndMarkets.com’s offering. This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions. Is genomic cancer testing bouncing back? […]

The post Global Genetic Testing Markets, Applications and Technologies Report 2022 – ResearchAndMarkets.com appeared first on Fintech News.

DUBLIN–(BUSINESS WIRE)–The “The Market for CRISPR/Cas9 Genome Editing Products” report has been added to ResearchAndMarkets.com’s offering. This report provides an in-depth and up-to-date look into scientists’ use of the genome editing tool, CRISPR/Cas9. Our survey reveals that while the market is growing steadily, there are challenges confronting suppliers. For instance, Bioinformatics found that over a […]

The post Global CRISPR/Cas9 Genome Editing Products Market Report: Market Analysis, Survey Data, Toolbox for CRISPR/Cas9 Experiments, Future Needs, Competitive Landscape – ResearchAndMarkets.com appeared first on Fintech News.

GE Healthcare announced on December 21, 2021, that it has completed the $1.45 billion acquisition of BK Medical from Altaris Capital Partners.  According to the press release, the acquisition expands GE Healthcare’s $3 billion ultrasound business from diagnostics into surgical and therapeutic interventions and adds to GE Healthcare’s capability in the fast-growing advanced surgical visualization segment. The acquisition further boosts GE Healthcare’s presence within the field of precision health, which refers to the tailoring of treatments to patients based on their medical histories, genetic makeup, and other factors and has a market that is valued in the tens of billions of dollars based on an article published on GE Healthcare’s website.

BK Medical is a global intraoperative imaging and surgical navigation company headquartered in Boston and Copenhagen.  Through its ultrasound technology and software algorithms, BK Medical enables surgeons to make real-time, data-based decisions during surgical procedures, including applications in general surgery, neurosurgery and spine, robotic-assisted surgery, colorectal surgery and urology.  BK Medical has more than 650 employees and has protected its technology with more than 136 patent families.

When the deal was first announced in September 2021, GE Healthcare’s President and CEO, Kieran Murphy, emphasized:

Ultrasound today forms an integral part of many care pathways, and BK Medical is a strategic and highly complementary addition to our growing and profitable Ultrasound business. This transaction helps GE Healthcare continue to expand beyond diagnostics into surgical and therapeutic interventions, simplifying decision-making for clinicians and equipping them with greater insights to deliver faster, more personalized care for their patients—representing another step toward delivering precision health.

The acquisition of BK Medical is GE Healthcare’s second acquisition in 2021 within the field of precision health.  In May 2021, GE Healthcare announced the acquisition of Zionexa, a company headquartered in France that develops and commercializes in-vivo biomarkers for guiding targeted therapies in oncology.

The post Acquisition of BK Medical Expands GE Healthcare’s Precision Health Presence appeared first on Knobbe Medical.

Charlotte medtech company releases a year end review discussing key figures, record growth, and what’s to come in 2022

(PRWeb January 05, 2022)

Read the full story at https://www.prweb.com/releases/medshift_releases_end_of_year_numbers_and_2021_company_growth/prweb18418445.htm